“…Intravenous magnesium has been used for treatment and prevention of ventricular tachycardia (8,11), ventricular fibrillation (10,13), and polymorphic ventricular tachycardia (7,12). Because QTc prolongation is more often present in women, we suggested that the beneficial effect of magnesium could be more pronounced in female patients (14). Pathophysiologic mechanisms may include antagonism at the L-and T-type calcium channels (15), membrane stabilization (16), reduced frequency of ventricular ectopic beats (17,18), and conversion to sinus rhythm (7,8,10,19,20).…”